People

Bacterial glycoprotein antigens for vaccine development


Anders Boysen,

CEO, Co-founder and Co-inventor


Anders Boysen is Chief Executive Officer and Co-inventor of GlyProVac’s proprietary BEMAP technology. Anders Boysen focus on the technical and scientific aspects of GlyProVac ApS operations. Prior to founding GlyProVac ApS, Anders Boysen over the last four years worked to establish proof of concept of the GlyProVac hypothesis and technically mature the lead antigen at University of Southern Denmark. Anders Boysen holds a Ph.D. in molecular biology and has more than 15 years of experience in the fields of molecular microbiology, human bacterial pathogens and biological mass spectrometry, both in academia and in the Danish vaccine development company ACE Biosciences Aps.


E-mail: boysen@GlyProVac.com

Ann Zahle Andersen,

CBDO and Co-founder


Ann Zahle Andersen is chief business development officer at GlyProVac ApS with responsibility for IP, contracts and financial aspects of GlyProVac ApS operations. Prior to founding GlyProVac ApS, Ann Zahle Andersen has been involved in business development of the GlyProVac hypothesis and lead antigen since the inception of the BEMAP method in 2013. Ann is an ASTP certified technology transfer professional with a Ph.D. in Biochemistry, experience in the field of microbiology and food borne bacteria as well as 5 years of experience in all aspects of business development of research-based inventions.


E-mail: zahle@GlyProVac.com

Mette Thorsing,

Scientist

 

Mette Thorsing works part time in GlyProVac and is in charge of the company’s cloning program. From more than 10 years of experience in the fields of molecular microbiology, bacterial physiology and human pathogens, she has accumulated knowledge and skills that are put to use in the laboratory and in the planning of GlyProVac’s scientific operations. Mette holds a Ph.D in molecular microbiology.


E-mail: thorsing@GlyProVac.com

Thøger Jensen Krogh,

IT and Bioinformatics

 

Thøger Jensen Krogh is part time in GlyProVac, while also being a Ph.D. student in Molecular Microbiology section at University of Southern Denmark with focus on Microbiology and Bioinformatics. He is a skilled self-taught programmer in HTML, R and is currently increasing his experience with Python. He uses his cross disciplinary skillset to develop bioinformatics tools and solutions to support BEMAP based GlyProVac glyco-protein analysis. In addition, he maintains the IT infrastructure and homepage of GlyProVac.

Board of directors



Anders Boysen, CEO, Co-founder and Co-inventor

Ann Zahle Andersen, CBDO and Co-founder

Kirsten Winther, Investment and Portfolio manager at Syddansk Innovation

Kirsten Winther,

Chairman of the board

 

Kirsten Winther is investment manager at Syddansk Innovation (SDI). SDI is a micro venture fund investing in high tech start-ups in the pre-seed face. Kirsten is responsible for SDI´s investment in a portfolio of start-ups covering the field of biotech, medtech, IoT and robotics. Prior to joining SDI, Kirsten has gained experience in the fields of business development, M&A, sales management and investment in energy projects, both in large corporations and as commercial director and co-investor in a start-up within greentech. Kirsten holds a MSc(econ).

Copyright © All Rights Reserved